Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Operating Costs and Expenses:
General and administrative	$ 1,218	$ 1,890	$ 4,154	$ 4,270
Research and development	3,693	1,475	9,247	3,796
Total Operating Costs and Expenses	4,911	3,365	13,401	8,066
Loss from Operations	(4,911)	(3,365)	(13,401)	(8,066)
Other Income (Expense):
Interest income	1	11	2	32
Other income (expense)	0	(14)	95	(59)
Total Other Income (Expense)	1	(3)	97	(27)
Net Loss	(4,910)	(3,368)	(13,304)	(8,093)
Net Loss Attributable to Non-controlling Interest	0	0	0	0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	$ (4,910)	$ (3,368)	$ (13,304)	$ (8,093)
Net Loss Per Share - Basic and Dilutive (in dollars per share)	$ (0.08)	$ (0.08)	$ (0.23)	$ (0.18)
Net Loss Per Share Attributable to Synthetic Biologics, Inc. and Subsidiaries (in dollars per share)	$ (0.08)	$ (0.08)	$ (0.23)	$ (0.18)
Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares)	58,453,528	44,654,414	58,356,025	44,636,935